{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:12:07Z","timestamp":1771668727662,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Colombiana de Psiquiatr\u00eda (English ed.)"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.rcpeng.2022.03.004","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T11:27:06Z","timestamp":1723289226000},"page":"184-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Activation syndrome in children and adolescents treated with selective serotonin reuptake inhibitors"],"prefix":"10.1016","volume":"53","author":[{"given":"Diana Marcela","family":"Pulzara Velasco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Ospina-Pinillos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rcpeng.2022.03.004_bib0005","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0024-3205(74)90345-2","article-title":"A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine","volume":"15","author":"Wong","year":"1974","journal-title":"Life Sci"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0010","first-page":"804","article-title":"A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy). N-methyl-3-phenylpropylamine","volume":"193","author":"Wong","year":"1975","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0038550","article-title":"A brief history of the development of antidepressant drugs: from monoamines to glutamate","volume":"23","author":"Hillhouse","year":"2015","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0020","series-title":"Seminars in Clinical Psychopharmacology","author":"Haddad","year":"2020"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bcp.2015.03.011","article-title":"Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs","volume":"95","author":"Dale","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0030","unstructured":"Stahl Online. Available from: https:\/\/stahlonline.cambridge.org\/essential_4th_chapter.jsf?page=chapter7_introduction.htm&name=Chapter%207&title=General%20principles%20of%20antidepressant%20%20action#c02598-7-1. Accessed 15 Nov 2020."},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2014.01.064","article-title":"Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells","volume":"727","author":"Ishima","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0040","first-page":"26F","article-title":"Antidepressants for pediatric patients","volume":"18","author":"Dwyer","year":"2019","journal-title":"Curr Psychiatry"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0045","first-page":"50","article-title":"Antidepressant-induced activation in children and adolescents: risk, recognition and management","volume":"48","author":"Luft","year":"2018","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s40501-015-0034-9","article-title":"SSRI-induced activation syndrome in children and adolescents\u2014what is next?","volume":"2","author":"Amitai","year":"2015","journal-title":"Curr Treat Options Psychiatry"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0055","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00213-006-0642-6","article-title":"Risk of adverse behavioral effects with pediatric use of antidepressants","volume":"191","author":"Goodman","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/cap.2008.040","article-title":"Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents","volume":"19","author":"Reinblatt","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0065","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.psychres.2014.11.070","article-title":"A pilot study of actigraphy as an objective measure of SSRI activation symptoms: results from a randomized placebo controlled psychopharmacological treatment study","volume":"225","author":"Bussing","year":"2015","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/cap.1990.1.193","article-title":"Behavioral side effects of fluoxetine in children and adolescents","volume":"1","author":"Riddle","year":"1990","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0075","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJM200104263441703","article-title":"Fluvoxamine for the treatment of anxiety disorders in children and adolescents","volume":"344","author":"Pine","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0080","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/104454603322163862","article-title":"A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors","volume":"13","author":"Wilens","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0085","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000345316","article-title":"Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review","volume":"82","author":"Offidani","year":"2013","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0090","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/cap.2006.16.159","article-title":"Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents","volume":"16","author":"Safer","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/cap.2007.0086","article-title":"Tolerability of selective serotonin reuptake inhibitors in thirty-nine children under age seven: a retrospective chart review","volume":"17","author":"Zuckerman","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0100","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/cap.2009.0126","article-title":"Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder","volume":"20","author":"Harris","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0105","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaac.2014.12.015","article-title":"Child\/adolescent anxiety multimodal study: evaluating safety","volume":"54","author":"Rynn","year":"2015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0110","unstructured":"Vitiello B. Principios de uso de medicaci\u00f3n psicotr\u00f3pica en ni\u00f1os y adolescentes. En: Rey JM, editor. Libro electr\u00f3nico de IACAPAP de salud mental en ni\u00f1os y adolescentes. Asociaci\u00f3n Internacional de Psiquiatr\u00eda y Profesiones Aliadas de Ni\u00f1os y Adolescentes. Published online 2016."},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/104454603322163871","article-title":"Drug-induced disinhibition in psychiatrically hospitalized children","volume":"13","author":"Carlson","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0120","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/JCP.0000000000000923","article-title":"Activation in children and adolescents treated with selective serotonin reuptake inhibitors: a weighty reason?","volume":"38","author":"Garcia-Delgar","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2515\/therapie:2004003","article-title":"Some aspects of genetic polymorphism in the biotransformation of antidepressants","volume":"59","author":"Br\u00f8sen","year":"2004","journal-title":"Therapie"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0135","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1038\/tp.2015.57","article-title":"The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression","volume":"5","author":"Rahn","year":"2015","journal-title":"Transl Psychiatry"},{"issue":"6","key":"10.1016\/j.rcpeng.2022.03.004_bib0140","doi-asserted-by":"crossref","DOI":"10.1002\/syn.22089","article-title":"Antidepressant medication exposure and 5-HT1A autoreceptor binding in major depressive disorder","volume":"73","author":"Metts","year":"2019","journal-title":"Synapse"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0145","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/archpsyc.1990.01810170019003","article-title":"Cerebrospinal fluid monoamine metabolites, aggression, and impulsivity in disruptive behavior disorders of children and adolescents","volume":"47","author":"Kruesi","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0150","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0006-3223(01)01170-2","article-title":"Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels","volume":"50","author":"Placidi","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0155","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/11591660-000000000-00000","article-title":"Antidepressants and psychostimulants in pediatric populations: is there an association with mania?","volume":"13","author":"Goldsmith","year":"2011","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2217\/14796708.4.1.87","article-title":"Antidepressant-coincident mania in children and adolescents treated with selective serotonin reuptake inhibitors","volume":"4","author":"Joseph","year":"2008","journal-title":"Future Neurol"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0165","article-title":"Depression preceding diagnosis of bipolar disorder","volume":"11","author":"O\u2019Donovan","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0175","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jad.2003.12.011","article-title":"Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review","volume":"82","author":"Faedda","year":"2004","journal-title":"J Affect Disord"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0180","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bdi.12113","article-title":"Antidepressant tolerability in anxious and depressed youth at high risk for bipolar disorder: a prospective naturalistic treatment study","volume":"16","author":"Strawn","year":"2014","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0185","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archpedi.158.8.773","article-title":"Age effects on antidepressant-induced manic conversion","volume":"158","author":"Martin","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0190","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/archpedi.159.3.298-a","article-title":"Risk of mania with antidepressants","volume":"159","author":"Baldessarini","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0195","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10566-010-9095-5","article-title":"Development and psychometric evaluation of the treatment-emergent activation and suicidality assessment profile","volume":"39","author":"Reid","year":"2010","journal-title":"Child Youth Care Forum"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0200","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4088\/PCC.v06n0206","article-title":"Suicidality as a possible side effect of antidepressant treatment","volume":"6","author":"Culpepper","year":"2004","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0205","first-page":"355","article-title":"Antidepressants and suicide in adolescents and adults","volume":"34","author":"McCain","year":"2009","journal-title":"Pharm Ther"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0210","unstructured":"FDA. Suicidality in children and adolescents being treated with antidepressant medications. Available from: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/suicidality-children-and-adolescents-being-treated-antidepressant-medications. Accessed 15 Nov 2020."},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0215","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpsychires.2015.10.006","article-title":"Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial","volume":"71","author":"Reid","year":"2015","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0220","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1542\/peds.2005-0074","article-title":"The Food and Drug Administration\u2019s deliberations on antidepressant use in pediatric patients","volume":"116","author":"Leslie","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0225","doi-asserted-by":"crossref","first-page":"g3596","DOI":"10.1136\/bmj.g3596","article-title":"Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study","volume":"348","author":"Reid","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0230","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/appi.ajp.2007.07030454","article-title":"Early evidence on the effects of regulators\u2019 suicidality warnings on SSRI prescriptions and suicide in children and adolescents","volume":"164","author":"Gibbons","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0235","doi-asserted-by":"crossref","first-page":"202","DOI":"10.9740\/mhc.2015.09.202","article-title":"Antidepressants and suicidality: history, the black-box warning, consequences, and current evidence","volume":"5","author":"Noel","year":"2015","journal-title":"Ment Health Clin"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0240","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4088\/JCP.08m04607","article-title":"Suicidal events in the Treatment for Adolescents with Depression Study (TADS)","volume":"70","author":"Vitiello","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0245","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.psc.2016.04.002","article-title":"Antidepressants and suicidality","volume":"39","author":"Brent","year":"2016","journal-title":"Psychiatr Clin North Am"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0250","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/appi.ajp.2010.10050718","article-title":"Clinical and psychosocial predictors of suicide attempts and nonsuicidal self-injury in the Adolescent Depression Antidepressants and Psychotherapy Trial (ADAPT)","volume":"168","author":"Wilkinson","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0255","first-page":"60","article-title":"SSRIs and SNRIs: a review of the discontinuation syndrome in children and adolescents","volume":"20","author":"Hosenbocus","year":"2011","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0260","first-page":"69","article-title":"SSRIs-related behavioural syndromes in children and adolescents","volume":"25","author":"Naguy","year":"2016","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0265","unstructured":"ParentsMedGuide.org. http:\/\/parentsmedguide.org\/. Accessed 15 Nov 2020."},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0270","first-page":"4","article-title":"Update on the use of SSRIs and SNRIs with children and adolescents in clinical practice","volume":"25","author":"Jane Garland","year":"2016","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0275","first-page":"141","article-title":"Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and ongoing management","author":"Cheung","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0280","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.npp.1300958","article-title":"ACNP task force report on SSRIs and suicidal behavior in youth","volume":"31","author":"Mann","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0285","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/jama.292.3.338","article-title":"Antidepressants and the risk of suicidal behaviors","volume":"292","author":"Jick","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0290","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/0706743716659276","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special populations: youth, women, and the elderly","volume":"61","author":"MacQueen","year":"2016","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0295","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jama.292.7.807","article-title":"Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial","volume":"292","author":"March","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0300","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamapediatrics.2017.3036","article-title":"Comparative effectiveness and safety of cognitive behavioral therapy and pharmacotherapy for childhood anxiety disorders: a systematic review and meta-analysis","volume":"171","author":"Wang","year":"2017","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0305","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jpsychires.2020.03.008","article-title":"Psychosocial risk factors and outcomes associated with suicide attempts in childhood: a retrospective study","volume":"125","author":"Itzhaky","year":"2020","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.rcpeng.2022.03.004_bib0310","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00127-019-01772-0","article-title":"Social context and change in suicide ideation in a community sample of youths","volume":"55","author":"Kasen","year":"2020","journal-title":"Soc Psychiatry Psychiatr Epidemiol"}],"container-title":["Revista Colombiana de Psiquiatr\u00eda (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530312024000377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530312024000377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T13:21:41Z","timestamp":1724678501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530312024000377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2530312024000377"],"URL":"https:\/\/doi.org\/10.1016\/j.rcpeng.2022.03.004","relation":{},"ISSN":["2530-3120"],"issn-type":[{"value":"2530-3120","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation syndrome in children and adolescents treated with selective serotonin reuptake inhibitors","name":"articletitle","label":"Article Title"},{"value":"Revista Colombiana de Psiquiatr\u00eda (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcpeng.2022.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rcp.2022.03.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Asociaci\u00f3n Colombiana de Psiquiatr\u00eda.","name":"copyright","label":"Copyright"}]}}